Company Profile
Fulgent Genetics, Inc. Stock Price, News & Analysis
- Ticker:
- FLGT
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
18.55 USD (+0.11%)
Close
Last updated: August 6, 2026
531M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, FLGT was little changed and closed at $18.55. No new same-company headline was identified in the current news window.
Company overview
Precision Medicine Business
Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization.
Laboratory Services
Fulgent provides technical laboratory testing and physician interpretation services. Its operations include genetic and specialty diagnostic capabilities serving healthcare providers, institutions and other customers.
Oncology Therapeutics
The therapeutic business uses nanoencapsulation and targeted-delivery technology to improve the pharmacokinetics and therapeutic window of cancer drugs. Clinical candidates FID-007 and FID-022 represent the lead applications of this platform.
Future catalysts
Phase 2 FID-007 data in a rapid oral presentation at the 2026 ASCO Annual Meeting.
Recent news
- 01
Fulgent Reports Second Quarter 2026 Financial Results
Source: Fulgent Genetics, Inc.
- 02
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Source: Fulgent Genetics, Inc.
- 03
Fulgent Presents Updated FID-007 Data at ASCO 2026
Source: Fulgent Genetics, Inc.
- 04
- 05
Fulgent Reports First Quarter 2026 Financial Results
Source: Fulgent Genetics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fulgent Genetics, Inc. (FLGT)?
Fulgent Genetics, Inc. (FLGT) most recently closed at 18.55 USD, a +0.11% move versus the previous session.
What is the market cap of Fulgent Genetics, Inc. (FLGT)?
Fulgent Genetics, Inc. currently has a market capitalization of 531M USD on BioPharmSignal.
What does Fulgent Genetics, Inc. do?
Precision Medicine Business Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization. Laboratory Services Fulgent provides technical laboratory testing and physician interpretation...
On which exchange is FLGT stock listed?
Fulgent Genetics, Inc. (FLGT) is associated with NASDAQ, United States, MedTech.
What is FID-007?
Phase 2 FID-007 data in a rapid oral presentation at the 2026 ASCO Annual Meeting.
Which conditions is Fulgent Genetics, Inc. targeting with FID-007?
Fulgent Genetics, Inc. is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Fulgent Genetics, Inc. describe recent progress with FID-007?
Phase 2 FID-007 data in a rapid oral presentation at the 2026 ASCO Annual Meeting.
What is FID-022?
Clinical candidates FID-007 and FID-022 represent the lead applications of this platform.